Literature DB >> 2893391

Preliminary evaluation of manassantin A, a potential neuroleptic agent from Saururus cernuus.

K V Rao1, V N Puri, P K Diwan, F M Alvarez.   

Abstract

Manassantin A (MNS-A), a novel dineolignan isolated from Saururus cernuus was evaluated for its central depressant effects. Intraperitoneal (IP) administration of MNS-A to mice at nontoxic doses caused a decrease in spontaneous motor activity and inhibition of amphetamine-induced stereotypy, with an ED50 of 0.21 +/- 0.02 mg/kg for its antiamphetamine activity. Doses of MNS-A up to the LD50 did not produce catalepsy and ptosis as were observed with haloperidol used as a reference drug. The compound caused a dose-dependent hypothermia, while haloperidol was not very effective in this test. Potentiation of pentobarbital-sleeping time was observed to be of comparable degree with both drugs. In spite of the higher toxicity (acute LD50 5.4 +/- 0.2 mg/kg, IP) than that shown by haloperidol, the somewhat selective neuroleptic profile of MNS-A makes it an interesting candidate for more detailed studies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2893391     DOI: 10.1016/0031-6989(87)90117-2

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN: 0031-6989


  4 in total

1.  Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1.

Authors:  Chowdhury Faiz Hossain; Yong-Pil Kim; Scott R Baerson; Lei Zhang; Richard K Bruick; Kaleem A Mohammed; Ameeta K Agarwal; Dale G Nagle; Yu-Dong Zhou
Journal:  Biochem Biophys Res Commun       Date:  2005-08-05       Impact factor: 3.575

Review 2.  The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Aamir Ahmad; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2012-05-10

3.  Manassantin B shows antiviral activity against coxsackievirus B3 infection by activation of the STING/TBK-1/IRF3 signalling pathway.

Authors:  Jae-Hyoung Song; Jae-Hee Ahn; Seong-Ryeol Kim; Sungchan Cho; Eun-Hye Hong; Bo-Eun Kwon; Dong-Eun Kim; Miri Choi; Hwa-Jung Choi; Younggil Cha; Sun-Young Chang; Hyun-Jeong Ko
Journal:  Sci Rep       Date:  2019-06-28       Impact factor: 4.379

4.  LXY6090 - a novel manassantin A derivative - limits breast cancer growth through hypoxia-inducible factor-1 inhibition.

Authors:  Fangfang Lai; Qian Liu; Xiaoyu Liu; Ming Ji; Ping Xie; Xiaoguang Chen
Journal:  Onco Targets Ther       Date:  2016-06-24       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.